COYA 301
Undisclosed (Treg Enhancing Biologic)
Not DisclosedPipeline Asset
Key Facts
Indication
Undisclosed (Treg Enhancing Biologic)
Phase
Not Disclosed
Status
Pipeline Asset
Company
About Coya Therapeutics
Coya Therapeutics is pioneering a novel approach to treating chronic inflammatory diseases by targeting and enhancing the function of regulatory T cells (Tregs). The company has generated strong proof-of-concept data in Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, with its lead biologic candidate, COYA 302, advancing in clinical trials for ALS and Frontotemporal Dementia (FTD). As a public, clinical-stage biotech, Coya is leveraging its multi-modality Treg platform to address significant unmet needs in large neurodegenerative and autoimmune markets.
View full company profile